Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Faricimab cuts through the fluid. A Swiss real-world study found that faricimab significantly reduced macular edema in patients with retinal vein occlusion over 6 months — both in treatment-naïve eyes and those previously on other anti-VEGF drugs. Vision improved in naïve patients, and the drug's safety profile looked solid with no cases of intraocular inflammation or vasculitis reported.
Faricimab shows real-world promise for macular edema from retinal vein occlusion
A retrospective study from 10 Swiss centers found that faricimab (Vabysmo, Roche) delivered meaningful results for patients with macular edema secondary to retinal vein occlusion over a 6-month period. Researchers analyzed outcomes in 99 eyes that had switched from other anti-VEGF therapies and 13 treatment-naïve eyes — a population described as "particularly challenging and clinically relevant" given their high baseline visual acuity and prior treatment exposure.
Both groups showed significant reductions in central subfield and central retinal thickness, with macular fluid resolving across all measurement zones. In treatment-naïve eyes, best corrected visual acuity improved from roughly 20/60 to 20/40, while previously treated eyes remained stable — a reminder that anatomical improvement doesn't always translate to functional gains.
By the Numbers
Why it matters: With faricimab's approval for retinal vein occlusion–related macular edema still relatively new, real-world data have been scarce. This study adds early evidence supporting faricimab's dual inhibition mechanism as a viable option — even for patients who haven't responded fully to prior anti-VEGF treatments.
